NCT02799095: A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for Part A
Exclusions: Untreated active symptomatic brain metastases requiring steroids- see trial for details

Comments are closed.

Up ↑